Telix Pharmaceuticals LimitedTLX
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · Australia · telixpharma.com
Commercial-stage global radiopharmaceutical company advancing targeted theranostics for cancer; its commercial franchise is anchored by the PSMA prostate-cancer imaging agents Illuccix and Gozellix, with three therapeutic assets in pivotal trials. Nasdaq line is a Level II ADR (1 ADS = 1 ordinary share); primary listing ASX: TLX.
Key ratios
Operating cash flow growth
-91.4%TTM
2024
92.6%
EPS growth
-91.1%TTM
2024
650.8%
FCF / Sales
-5.3%TTM
2025
-5.3%2024
3.6%2023
2.4%
Net margin
-0.9%TTM
2025
-0.9%2024
6.5%2023
1.3%
ROA
1.2%TTM
2025
1.2%2024
5.7%2023
9.7%
ROE
-1.9%TTM
2025
-1.9%2024
14.8%2023
5.4%
Revenue growth
55.6%2025
2024
55.1%2023
205.3%
Recent news
FDA Approves Telix's Brain Cancer Imaging Drug Pixclara
Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
Telix to Host R&D Day in New York City on September 22, 2026
Telix H1 2026 Results: Investor Webcast Notification
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
Track TLX in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer